SUBSCRIBE
SUBSCRIBE

Inozyme Pharma

IN THE PRESS
Inozyme Pharma was acquired by BioMarin Pharmaceuticals in July 2025.
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
November 6, 2024
 · 
14 min read
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
October 24, 2024
 · 
10 min read
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
October 17, 2024
 · 
6 min read
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
October 7, 2024
 · 
6 min read
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
September 27, 2024
 · 
11 min read
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
August 30, 2024
 · 
1 min read
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
August 6, 2024
 · 
13 min read
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
July 25, 2024
 · 
5 min read
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
July 2, 2024
 · 
6 min read
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
Inozyme Pharma, Inc. today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 from 12:30-12:55 pm ET.
May 30, 2024
 · 
1 min read
NEWS
Drug Development
Clinical Catch-Up: January 4-8
The new year began with a fairly low level of clinical trial news. Here’s a look.
January 8, 2021
 · 
5 min read
 · 
Mark Terry
Business
BioSpace Movers & Shakers, November 13
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
November 12, 2020
 · 
7 min read
 · 
Alex Keown
Business
BioSpace Movers & Shakers, Oct. 16
Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.
October 15, 2020
 · 
7 min read
 · 
Alex Keown
Investor
Genetown
Cambridge Startup Inozyme Nabs $49M and a Roster Packed With Seasoned Vets
The $49M in Series A funding will be used to develop the company’s enzyme replacement therapies for two rare diseases affecting infants and children and push the treatments into the clinic.
November 15, 2017
 · 
2 min read
 · 
Alex Keown
Load More